IDSA News - May 2013  (Plain Text Version)

Return to Graphical Version


In this issue:
Patient Care and Science
•  Now Online: Updated Opportunistic Infection Guidelines for HIV-Infected Patients
•  Three Compounding Pharmacies Announce Voluntary Recalls
Clinical Practice Management
•  Coming in June: HCV Webinar Series from IDSA
Science Speaks Blog
•  HPTN Annual Meeting: Search for New HIV Prevention Strategies
•  Trial in Zambia, South Africa to Examine Universal HIV Testing, Care Access, and Prevention Services
•  Gaps in President’s Budget Request Will Reverse Gains in Global HIV, TB Efforts
Policy and Advocacy
•  Society Urges Strong Funding for ID Research, Public Health Programs
•  IDSA Leads Support for Advanced Molecular Detection Initiative
Your Colleagues
•  Check Out “My IDSA” for Latest Member News
Education and Resources
•  Lyme Disease Resources from CDC
Top Stories
•  From the President: How IDSA Supports Public Health
•  FDA Requires IND for Fecal Microbiota Transplantation
•  EIN Update: 13-Valent Pneumococcal Conjugate Vaccine in the Hospital Setting
•  IDSA Journal Club


Now Online: Updated Opportunistic Infection Guidelines for HIV-Infected Patients

Updated guidelines for the prevention and treatment of opportunistic infections (OIs) in adults and adolescents infected with HIV are now available online. Developed by the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and HIVMA, the guidelines were last updated in 2009.

The guidelines are intended for clinicians, other health care providers, HIV-infected patients, and policy makers in the United States. Key changes include:

  • New information on the diagnosis and management of immune reconstitution inflammatory syndrome (IRIS), particularly as it relates to tuberculosis and cryptococcosis
  • New guidance for managing IRIS related to each OI
  • Updated information on the management of hepatitis B and hepatitis C
  • Updated immunization strategies for preventing pneumococcal disease and human papillomavirus, reflecting the availability of new vaccines and new data
  • Updated drug interaction information, particularly regarding antiretroviral medications approved since the last update of the guidelines

The guidelines also include tables at the end of each chapter and summary tables at the end of the document that list therapeutic options for preventing and treating OIs, adverse drug reactions, pharmacokinetic interactions, dosing recommendations in patients with renal insufficiencies, and therapeutic considerations in pregnancy.

The update was developed by a panel of six co-editors representing NIH, CDC, and HIVMA, plus more than 100 expert panel members selected by the co-editors from government, academia, and the health care community.

The full guidelines are available on the website. Visit the practice guidelines section of the IDSA website for additional IDSA/HIVMA practice guidelines and related resources.